Glutamine 57 at the complementary face of the binding site governs the high selectivity of morantel for A7 nicotinic receptorsA

M BARTOS,; PRICE K; LUMMIS S; BOUZAT C

cHICAGO

Conferencia; 39 Annual Meeting Society for Neuroscience (SFN).; 2009

Society for Neuroscience

Glutamine 57 at the complementary face of the binding site governs the high selectivity of morantel for a7 nicotinic receptors   Mariana Bartos1, Kerry L. Price2, Sarah C.R. Lummis2, and Cecilia Bouzat1 1Instituto de Investigaciones Bioquímicas, UNS-CONICET, Bahía Blanca 8000, Argentina; 2Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK   Nicotinic receptors (AChRs) play key roles in synaptic transmission. We explored activation of neuronal a7 and mammalian muscle AChRs by morantel and oxantel. Our results revealed a novel action of morantel as an agonist more potent than ACh of α7 AChRs. The EC50 for activation by morantel of both a7 and a7-5HT3A receptors is 7-fold lower than that determined for ACh. The minimum morantel concentration required to activate single a7-5HT3A channels is 6-fold lower than that of ACh, and activation episodes are more prolonged than in the presence of ACh. By contrast, oxantel is a weak agonist of a7 and a7-5HT3A, and both drugs are very low-efficacy agonists of muscle AChRs. The replacement of Gln57 in a7 by glycine, which is found in the equivalent position of the muscle AChR, decreases the efficacy for activation and turns morantel into a partial agonist. The reverse mutation in the muscle AChR (eG57Q) increases 7-fold the efficacy of morantel. The mutations do not affect activation by ACh or oxantel, indicating that this position is selective for morantel. In silico studies show that the tetrahydropyrimidinyl group, common to both drugs, is close to Trp149 of the principal face of the binding site, whereas the other cyclic group is proximal to Gln57 of the complementary face in morantel but not in oxantel.  Thus, position 57 at the complementary face is a key determinant of the differential selectivity of morantel for a7 and muscle AChRs. These results provide new information for further progress in drug design.